Monika Pury Oktora1, Sofa Dewi Alfian2,3, H Jens Bos2, Catharina Carolina Maria Schuiling-Veninga2, Katja Taxis2, Eelko Hak2, Petra Denig1. 1. Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen (UMCG), Groningen, The Netherlands. 2. Groningen Research Institute of Pharmacy, Unit of PharmacoTherapy, -Epidemiology and -Economics, University of Groningen, Groningen, The Netherlands. 3. Faculty of Pharmacy, Department of Pharmacology and Clinical Pharmacy, Universitas Padjadjaran, Jatinangor, Indonesia.
Abstract
AIMS: Polypharmacy is common in people with diabetes and is associated with the use of potentially inappropriate medication (PIM). This study aimed to assess trends in the prevalence of polypharmacy and PIM in older and middle-aged people with diabetes. METHODS: A repeated cross-sectional study using the University Groningen IADB.nl prescription database was conducted. All people aged 45 years and over who were treated for diabetes registered in the period 2012-2016 were included. Polypharmacy was assessed for three age groups. PIMs were assessed using Beers criteria for people ≥65 years old, and PRescribing Optimally in Middle-aged People's Treatments (PROMPT) criteria for 45-64 years old. Chi-square tests and regression analysis were applied. RESULTS: The prevalence of polypharmacy increased significantly in all age groups in the study period. In 2016, the prevalence of polypharmacy was 36.9% in patients aged 45-54 years, 50.3% in those aged 55-64 years, and 66.2% in those aged ≥65 years. The prevalence of older people with at least one PIM decreased by 3.1%, while in the middle-aged group this prevalence increased by 0.9% from 2012 to 2016. The most common PIMs in both age groups were the use of long-term high-dose proton pump inhibitors, benzodiazepines and strong opioids without laxatives. Of those, only benzodiazepines showed a decreasing trend. CONCLUSIONS: Polypharmacy increased in older and middle-aged people with diabetes. While the prevalence of PIM decreased over time in older age, this trend was not observed in middle-aged people with diabetes. Efforts are needed to decrease the use of PIMs in populations already burdened with many drugs, notably at middle age.
AIMS: Polypharmacy is common in people with diabetes and is associated with the use of potentially inappropriate medication (PIM). This study aimed to assess trends in the prevalence of polypharmacy and PIM in older and middle-aged people with diabetes. METHODS: A repeated cross-sectional study using the University Groningen IADB.nl prescription database was conducted. All people aged 45 years and over who were treated for diabetes registered in the period 2012-2016 were included. Polypharmacy was assessed for three age groups. PIMs were assessed using Beers criteria for people ≥65 years old, and PRescribing Optimally in Middle-aged People's Treatments (PROMPT) criteria for 45-64 years old. Chi-square tests and regression analysis were applied. RESULTS: The prevalence of polypharmacy increased significantly in all age groups in the study period. In 2016, the prevalence of polypharmacy was 36.9% in patients aged 45-54 years, 50.3% in those aged 55-64 years, and 66.2% in those aged ≥65 years. The prevalence of older people with at least one PIM decreased by 3.1%, while in the middle-aged group this prevalence increased by 0.9% from 2012 to 2016. The most common PIMs in both age groups were the use of long-term high-dose proton pump inhibitors, benzodiazepines and strong opioids without laxatives. Of those, only benzodiazepines showed a decreasing trend. CONCLUSIONS: Polypharmacy increased in older and middle-aged people with diabetes. While the prevalence of PIM decreased over time in older age, this trend was not observed in middle-aged people with diabetes. Efforts are needed to decrease the use of PIMs in populations already burdened with many drugs, notably at middle age.
Authors: Jordan Guillot; Christopher T Rentsch; Kirsha S Gordon; Amy C Justice; Julien Bezin Journal: Pharmacoepidemiol Drug Saf Date: 2022-07-15 Impact factor: 2.732
Authors: Natacha Christina de Araújo; Erika Aparecida Silveira; Brenda Godoi Mota; Rafael Alves Guimarães; Ana Carolina Figueiredo Modesto; Valéria Pagotto Journal: Int J Clin Pharm Date: 2022-07-27
Authors: Daniela A Rodrigues; Ana I Plácido; Ana Bárbara Tavares; Daniela Azevedo; Ramona Mateos-Campos; Adolfo Figueiras; Maria Teresa Herdeiro; Fátima Roque Journal: Curr Ther Res Clin Exp Date: 2022-07-13
Authors: Lvliang Lu; Keqin Yao; Jiaqi Chen; Yujie Yang; Kai Wang; Jing Zheng; Pi Guo; Yunpeng Cai; Qingying Zhang Journal: Front Public Health Date: 2022-09-20
Authors: Tuuli Elina Lehti; M-O Rinkinen; U Aalto; H M Roitto; M Knuutila; H Öhman; H Kautiainen; H Karppinen; R Tilvis; T Strandberg; K H Pitkälä Journal: Drugs Aging Date: 2021-08-13 Impact factor: 3.923